logo

Alexion Pharmaceuticals Inc. (ALXN)



Trade ALXN now with
  Date
  Headline
6/11/2018 7:31:18 AM Alexion Pharma And Complement Pharma Today Announce Partnership To Co-develop Preclinical C6 Complement Inhibitor CP010
5/25/2018 1:06:30 AM Alexion Says Offer Accepted By Shareholders Representing 97.7% Of Shares And Votes In Wilson Therapeutics
5/24/2018 10:36:58 AM Prevail Therapeutics Appoints Francois Nader To Its Board
4/26/2018 9:42:05 AM Alexion Pharmaceuticals Inc. (ALXN) Has Raised Its 2018 EPS Estimate To 6.75 - 6.90 From 6.60 - 6.80
4/26/2018 9:41:39 AM Alexion Pharmaceuticals Inc. (ALXN) Has Raised Its 2018 Revenue Estimate To $3.925 - $3.985 Bln From $3.850 - $3.950 Bln
4/26/2018 6:33:23 AM Alexion Q1 Total Revenues $930.9 Mln, Up 7%
4/11/2018 1:58:50 AM Alexion Announces Recommended Public Cash Offer To Wilson Therapeutics
3/15/2018 6:32:51 AM Alexion Reports Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210
2/9/2018 7:45:40 AM RBC Capital Markets Is Lowering Alexion Pharmaceuticals Inc. (ALXN) FY19 Rev. Estimate To 4.64 Billion From 4.70 Billion
2/9/2018 7:45:27 AM RBC Capital Markets Is Increasing Alexion Pharmaceuticals Inc. (ALXN) FY18 Rev. Estimate To 3.92 Billion From 3.91 Billion
2/9/2018 7:44:59 AM RBC Capital Markets Is Increasing Alexion Pharmaceuticals Inc. (ALXN) FY19 Estimate To 5.11 From 4.67
2/9/2018 7:44:49 AM RBC Capital Markets Is Increasing Alexion Pharmaceuticals Inc. (ALXN) FY18 Estimate To 3.98 From 3.03